Discontinuation of the double-blind, placebo-controlled randomized, phase III GORTEC 2022–01 trial of radiotherapy-cetuximab and xevinapant in patients with locally advanced squamous cell carcinoma of the head and neck, unfit for cisplatin
- 26 March 2026
- journal article
- research article
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 219, 111479
Abstract
No abstract availableKeywords
Funding Information
- Centre Henri Becquerel
- Merck KGaA
- National Institute of Clean-and-Low-Carbon Energy
- Hôpital Paris Saint-Joseph
This publication has 25 references indexed in Scilit:
- Chemoradiation therapy With Cisplatin Versus Cetuximab in Patients With Locoregionally Advanced Head and Neck Squamous Cell Cancer—Mature Results of the ARTSCAN III TrialInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2025
- 857O MACH-EGFR: Individual patient data (IPD) meta-analysis of anti-EGFR monoclonal antibodies (Ab) in patients (pts) with locally advanced (LA) squamous cell carcinomas of head and neck (SCCHN)Annals of Oncology, 2023
- Randomized Trial of Radiation Therapy With Weekly Cisplatin or Cetuximab in Low-Risk HPV-Associated Oropharyngeal Cancer (TROG 12.01) – A Trans-Tasman Radiation Oncology Group StudyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2021
- Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS–ESMO–ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2020
- Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 studyThe Lancet Oncology, 2020
- Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trialThe Lancet, 2019
- Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trialThe Lancet, 2019
- Regulation of XIAP Translation and Induction by MDM2 following IrradiationCancer Cell, 2009
- Expression of the IAP protein family is dysregulated in pancreatic cancer cells and is important for resistance to chemotherapyInternational Journal of Cancer, 2007
- Translational upregulation of X-linked inhibitor of apoptosis (XIAP) increases resistance to radiation induced cell deathOncogene, 2000